See more : Yumanity Therapeutics, Inc. (YMTX) Income Statement Analysis – Financial Results
Complete financial analysis of Longboard Pharmaceuticals, Inc. (LBPH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Longboard Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Mattel, Inc. (MAT) Income Statement Analysis – Financial Results
- Paslin Digital Technology Co., Ltd. (600215.SS) Income Statement Analysis – Financial Results
- Triple-S Management Corporation (GTS) Income Statement Analysis – Financial Results
- Jubilant Flame International, Ltd. (JFIL) Income Statement Analysis – Financial Results
- African Gold Limited (A1G.AX) Income Statement Analysis – Financial Results
Longboard Pharmaceuticals, Inc. (LBPH)
About Longboard Pharmaceuticals, Inc.
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical product candidates include LP659 and LP143, which focuses on developing therapies for multiple neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 5.00K | 5.00K | 1.00K | 0.00 |
| Gross Profit | -5.00K | -5.00K | -1.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 43.75M | 34.64M | 19.77M | 4.63M |
| General & Administrative | 13.01M | 10.16M | 8.07M | 9.77M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.01M | 10.16M | 8.07M | 9.77M |
| Other Expenses | 0.00 | 16.00K | -22.00K | 0.00 |
| Operating Expenses | 56.76M | 44.80M | 27.84M | 14.40M |
| Cost & Expenses | 56.76M | 44.80M | 27.84M | 14.40M |
| Interest Income | 2.41M | 837.00K | 64.00K | 0.00 |
| Interest Expense | 0.00 | 837.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 5.00K | 5.00K | 1.00K | 7.00M |
| EBITDA | -56.75M | -44.79M | -27.84M | -14.40M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -56.76M | -44.80M | -27.84M | -14.40M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.34M | 853.00K | 42.00K | 0.00 |
| Income Before Tax | -54.42M | -43.95M | -27.80M | -14.40M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -853.00K | -64.00K | -14.40K |
| Net Income | -54.42M | -43.09M | -27.73M | -14.40M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.39 | -2.51 | -1.62 | -0.82 |
| EPS Diluted | -2.39 | -2.51 | -1.62 | -0.82 |
| Weighted Avg Shares Out | 22.73M | 17.15M | 17.07M | 17.67M |
| Weighted Avg Shares Out (Dil) | 22.73M | 17.15M | 17.07M | 17.67M |
LONGBOARD PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Longboard Pharmaceuticals, Inc. - LBPH
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Longboard Pharmaceuticals, Inc. (NasdaqGM: LBPH) to H. Lundbeck A/S. Under the...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LBPH and ARC on Behalf of Shareholders
NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Longboard Pharmaceuticals, Inc. – LBPH
NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are...
LONGBOARD PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Longboard Pharmaceuticals, Inc. - LBPH
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Longboard Pharmaceuticals, Inc. (NasdaqGM: LBPH) to H. Lundbeck A/S. Under the...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LBPH and OB on Behalf of Shareholders
NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Longboard Pharmaceuticals, Inc. - LBPH
NEW YORK , Oct. 15, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are...
Longboard Set to be Acquired by Lundbeck for $2.6B, Stock Soars 52%
LBPH stock soars 52% on announcing that it is set to be acquired by Lundbeck for a total consideration of $2.6 billion to bolster the latter's neuro pipeline.
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Longboard Pharmaceuticals, Inc.
NEW YORK , Oct. 14, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Longboard Pharmaceuticals, Inc. (NASDAQ: LBPH) and its board of directors concerning the proposed acquisition of the company by H. Lundbeck A/S.
Dow Surges Over 200 Points; Longboard Pharmaceuticals Shares Jump
U.S. stocks traded higher toward the end of trading, with the S&P 500 gaining around 0.8% on Monday.
S&P 500 hits record high; Dow gains as Longboard Pharmaceuticals surges 51% and tech stocks rise
The S&P 500 rose to a new record high of 5,859 on Monday ahead of key corporate earnings later this week. At the time of writing, the S&P 500 index was 0.8% higher than the previous close.
Source: https://incomestatements.info
Category: Stock Reports